
Dr. Vikas Dua is a senior Paediatric Haematologist, Haemato-Oncologist and Bone Marrow Transplant specialist serving as Principal Director and Head of Paediatric Haematology, Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurugram. With more than 20 years of professional experience, he specialises in childhood blood disorders, paediatric cancers and advanced stem cell transplantation.
He completed his MBBS and MD in Paediatrics from Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak. He subsequently obtained an FNB in Paediatric Haematology and Oncology from Sir Ganga Ram Hospital, New Delhi, and completed specialised bone marrow transplant training at National University Hospital, Singapore, along with further exposure at St. Jude Children's Research Hospital, United States.
His clinical expertise includes paediatric leukaemia, lymphoma, thalassaemia, aplastic anaemia, haemophilia, sickle cell disease and other childhood blood disorders. He also specialises in matched sibling, unrelated donor and haploidentical bone marrow transplantation and other advanced cellular treatment approaches.
Dr. Dua has contributed extensively to the development of paediatric bone marrow transplant services in India. His professional background includes clinical research, specialist medical training and the development of advanced treatment programmes for children with complex haematological and oncological conditions.
Decades of expertise, proven results, and compassionate care — here is why patients from 50+ countries trust Dr. Vikas Dua for Hematology & BMT treatment in India.
Over 20 years of dedicated clinical experience with 5,000+ procedures. One of the most trusted names in Hematology & BMT in India.
Dr. Vikas Dua regularly treats patients from Africa, the Middle East, Central Asia, and Europe. Dedicated international patient support team available 24/7.
Practices at an internationally accredited hospital, ensuring patient safety standards that match the best hospitals in the USA and Europe.
World-class treatment at a fraction of USA, UK, or Australian prices. Transparent cost estimates provided before you travel.
Dr. Vikas Dua holds postgraduate qualifications from premier Indian institutions and has advanced fellowship training in Hematology & BMT.
Every case is personally reviewed. Treatment plans are tailored, transparent, and discussed in detail before you make any decisions or travel arrangements.
AML, CML, CLL, ALL, Hodgkin & Non-Hodgkin Lymphoma, Multiple Myeloma — treated with chemotherapy, targeted therapy & BMT.
Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders.
Cutting-edge immunotherapy using genetically modified T-cells for blood cancers that have relapsed after standard treatments.
Curative BMT for thalassemia major and sickle cell anemia in children and adults. Low-cost programs available across India.
Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.
HSCT (Hematopoietic Stem Cell Transplant) for aggressive Multiple Sclerosis — a disease-modifying treatment available in India.
Expert care for childhood leukemia, thalassemia, ITP, and inherited bone marrow failure syndromes.
Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with modern protocols.
Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and coagulopathies.
The most complex and potentially curative form of BMT where stem cells come from a matched donor. Used for leukemia, aplastic anemia, and inherited blood disorders.
Patient's own stem cells are harvested and reinfused after high-dose chemotherapy. Used for multiple myeloma and relapsed lymphomas.
Revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.
The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation.
Personalised chemotherapy and next-generation targeted agents for lymphoma, leukaemia, and related disorders.
Send your medical reports and get a personalised treatment plan. The team reviews cases from 50+ countries and responds within 24 hours.
Our team responds within 24 hours
Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.